AngioDynamics Inc expected to post a loss of 12 cents a share - Earnings Preview
AngioDynamics Inc
ANGO is expected to show a rise in quarterly revenue when it reports results on July 15 for the period ending May 31 2025The Latham New York-based company is expected to report a 4.6% increase in revenue to $74.256 million from $70.98 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for AngioDynamics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for AngioDynamics Inc is $16.00, about 40.8% above its last closing price of $9.48
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Feb. 28 2025 | -0.14 | -0.13 | 0.03 | Beat | 123.1 |
Nov. 30 2025 | -0.10 | -0.11 | -0.04 | Beat | 63.6 |
Aug. 31 2024 | -0.15 | -0.15 | -0.11 | Beat | 25 |
May. 31 2024 | -0.16 | -0.17 | -0.06 | Beat | 64 |
Feb. 29 2024 | -0.13 | -0.14 | -0.16 | Missed | -18.3 |
Nov. 30 2023 | -0.09 | -0.07 | -0.05 | Beat | 33.3 |
Aug. 31 2023 | -0.13 | -0.13 | -0.12 | Beat | 7.7 |
May. 31 2023 | 0.03 | 0.02 | 0.02 | Met | -11.1 |
This summary was machine generated July 11 at 12:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
